On July 29, 2025, Larimar Therapeutics, Inc. entered into an underwriting agreement for the sale of 18,750,000 shares of common stock at $3.20 per share, expecting to raise approximately $64.4 million. The underwriters exercised an option for additional shares, and the offering is set to close on July 31, 2025.